Lipoprotein(a) Emerges as Hidden Driver of Cardiovascular Risk in Chronic Kidney Disease
A new review argues that genetically determined lipoprotein(a) is a key driver of the residual cardiovascular risk that persists in ...
A new review argues that genetically determined lipoprotein(a) is a key driver of the residual cardiovascular risk that persists in ...
A pooled analysis of two placebo-controlled crossover trials shows that the SGLT-2 inhibitors empagliflozin and dapagliflozin modestly but significantly raise ...
Researchers have engineered ultrasmall citrate-coated gadolinium oxide nanoparticles that deliver more than double the T1 relaxivity of the clinical agent ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine